The report covered the source and evolution of technology, performance, PA66 industrial development trend, CPL industry dilemma and comparison of CPL-route HMDA and butadiene-route HMDA. The technology originates from Japan's Toray Industries, involves collaborative partnerships, and the company holds relevant patents. Commercially, cooperation agreements have been signed with two renowned enterprises. The report also addresses the current state of the PA66 industry and discusses challenges in the caprolactam sector, such as supply-demand imbalances and pricing issues, along with proposed solutions. Furthermore, it compares the characteristics of the caprolactam-based process with butadiene-based methods, emphasizing the advantages of the former and expressing openness to collaboration opportunities.